SCHEMBL7199674

SCHEMBL7199674

NC(=O)N1CCC(S(=O)(=O)c2ccc(Oc3ccccc3F)cc2)C(O)(C(=O)O)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 5/20 0.42
MMP13 P45452 5/20 0.42
PARP10 Q53GL7 2/20 0.41
FFAR1 O14842 1/20 0.41
MMP2 P08253 2/20 0.37
MMP3 P08254 2/20 0.37
MMP9 P14780 2/20 0.37
MMP14 P50281 2/20 0.37
HPGD P15428 1/20 0.36
MMP12 P39900 1/20 0.36
BTK Q06187 7/20 0.36
EGFR P00533 1/20 0.36
BMX P51813 1/20 0.36
ITK Q08881 1/20 0.36
LPAR1 Q92633 1/20 0.35
LPAR5 Q9H1C0 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
HTT P42858 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7206530 0.90 TSHR (0.45) MMP1MMP13MMP2MMP3MMP9
SCHEMBL7199692 0.89 PARP10 (0.41) MMP1MMP13PARP10MMP2MMP3
SCHEMBL7207163 0.89 MMP1 (0.45) MMP1MMP13PARP10MMP2MMP3
SCHEMBL7202596 0.89 MMP1 (0.54) MMP1MMP13FFAR1MMP2MMP3
SCHEMBL7199700 0.89 MMP1 (0.42) MMP1MMP13ALDH1A1LMNASMN1; SMN2
SCHEMBL7206509 0.84 SCN3A (0.45) MMP1MMP13PARP10
SCHEMBL7207978 0.84 PARP10 (0.45) MMP1MMP13PARP10MMP2MMP3
SCHEMBL7205673 0.83 MMP1 (0.39) MMP1MMP13ALDH1A1
SCHEMBL7203058 0.83 MMP9 (0.47) MMP1MMP13MMP2MMP3MMP9
SCHEMBL7204562 0.83 MMP13 (0.51) MMP1MMP13FFAR1MMP2MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608104-B2 Antiarthritic agents; anticancer agents PFIZER INC 2003-08-19 US disclosed
US-20020019534-A1 Gem substituted hydroxamic acids PFIZER INC. 2002-02-14 US disclosed
EP-1138680-A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors Pfizer Products Inc. (US) 2001-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019534-A1 Gem substituted hydroxamic acids MMP14, TOP2A, ADAMTS1 MMP1 8/4885MMP13 4/4885PARP10 1359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.